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Background. Nonocclusive mesenteric ischemia (NOMI) can evolve in a variety of low-flow states.
Although the mechanisms leading to NOMI-related intestinal necrosis are largely unknown,
circumstantial evidence suggests that excessive vasoconstriction and complement activation both play
important roles in this process. Because targeting of the circulatory malfunction of the splanchnic area
could be of therapeutic relevance, we set out to investigate the long-term effects of treatment with a
complement C5a antagonist in a rat model of partial aortic occlusion (PAO)-induced transient
mesenteric hypoperfusion.
Methods. The mean arterial pressure of the splanchnic area was kept between 30 and 40 mm Hg by 60
minutes of PAO in anesthetized male Sprague-Dawley rats. C5a inhibitor acetyl-peptide-A (AcPepA;
4 mg kg1 intravenously) or vehicle administration was initiated at the 45th minute of PAO. After
24 hours, the animals were reanesthetized to record the macrohemodynamics and ileal microcircula-
tion, and plasma and tissue samples were taken for determination of high-mobility group box protein-1
(HMGB-1), endothelin-1, tumor necrosis factor (TNF)-a levels, and small intestinal leukocyte infil-
tration. Epithelial structural changes were visualized by in vivo confocal laser scanning endomicro-
scopy.
Results. At 24 hours after PAO, mean arterial pressure, heart rate, and cardiac output were
significantly greater, the intestinal intramural microcirculation was significantly impaired, and
plasma HMGB-1, endothelin-1, TNF-a levels, the degree of epithelial damage and leukocyte
infiltration was increased. The AcPepA treatment moderated the hemodynamic and microcirculatory
changes, and decreased inflammatory activation and histologic signs of mucosal damage.
Conclusion. C5a inhibition ameliorated the potentially harmful local mesenteric hypoperfusion and
global long-term inflammatory consequences of PAO. This approach is of promise for use in NOMI-
associated situations. (Surgery 2016;159:960-71.)From the Institute of Surgical Research,a University of Szeged, Szeged, Hungary; the Department of Immu-
nology,b Nagoya City University Graduate School of Medical Sciences, Nagoya; and Choju Medical Institute,c
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URGERYstates. Although it may account for as many as
20–30% of cases of acute mesenteric ischemia,
various degrees of NOMI occur in patients with un-
stable systemic circulatory conditions, including
hemorrhagic shock,1 burn injury,2 pancreatitis,3
and the postoperative phase of cardiac and aortic
surgery.4 NOMI often remains undiagnosed.5
Information on the pathogenesis of NOMI is
rather scarce, but it is assumed that the potentially
life-threatening structural damage of the mucosa
evolves as a consequence of excessive and sus-
tained splanchnic vasoconstriction. Nonsurgical
management, however, is always challenging and
precarious, because no vasodilator agent has yet
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tinal barrier dysfunction and the subsequent
development of transmural gangrene.
Conservative therapy for NOMI is nonspecific
and is usually limited to hemodynamic support
and the correction of biochemical alterations.
Nevertheless, an increasing number of indirect
data suggest a central role for the activation of
complement system in the pathophysiologic
mechanisms. The decrease in perfusion and
oxygenation to the mucosal layer appears to
activate the complement cascade, which may be
one of the key elements of the innate inflamma-
tory response, accompanied by production of the
anaphylatoxins complement fragments C3a and
C5a.6 Chemotaxis and activation of the neutro-
phil granulocytes are the main effects of C5a gen-
eration,7 whereas the release of reactive oxygen
species and cytokines8,9 and smooth muscle
contraction may worsen the derangements of
the intramural microcirculation.
Our current knowledge of NOMI is based
mostly on clinical reports or deduced from acute
experimental studies involving the use of mesen-
teric artery occlusion.10 Our first experimental
goal was, therefore, to develop a reliable in vivo
rat model of NOMI of extramesenteric origin to
investigate the major components of local and sys-
temic circulatory reactions in a clinically relevant
time frame. We hypothesized that the inhibition
of C5a generation would offer a plausible way to in-
fluence the potentially detrimental consequences
of NOMI. In an earlier study with experimental
cardiac tamponade, we demonstrated activation
of the complement system leading to C3 deposits
in the small intestinal capillaries.11 Accordingly,
we set out to characterize the effects of the C5a in-
hibitor peptide acetyl-peptide-A (AcPepA)12 on
the macrocirculatory and microcirculatory
changes and inflammatory reactions 24 hours after
the initial insult leading to established low-flow
conditions in the splanchnic area.
MATERIALS AND METHODS
Animals. Experiments were performed under
sterile conditions on male, Sprague-Dawley rats
(average weight 350 g; n = 44) under sodium
pentobarbital anesthesia (50 mg kg1 intraperito-
neally), in adherence to the National Institutes of
Health guidelines and European Union directive
2010/63 for the protection of animals used for sci-
entific purposes. The study was approved by the
Ethical Committee for the Protection of Animals
in Scientific Research at the University of Szeged
(approval number: V/148/2013).Pilot studies. For instrumentation, anesthetized
animals were placed in a supine position on
heating pads. Tracheostomy was performed to
facilitate spontaneous breathing, and the right
jugular vein was cannulated with PE50 tubing for
drug administration and infusion of Ringer’s
lactate (10 mL kg1 h1). The left carotid artery
and the left femoral artery were cannulated for
mean measurements of mean arterial pressure
(MAP) and heart rate (HR). A thermistor-tip cath-
eter (PTH-01; Experimetria Ltd, Budapest,
Hungary) was positioned into the ascending aorta
through the right carotid artery for measurement
of cardiac output (CO), using a thermodilution
technique (SPEL Advanced Cardiosys 1.4, Experi-
metria Ltd). After a midline abdominal incision,
the proximal part of the abdominal aorta was
dissected free between the diaphragm and the
origin of the superior mesenteric artery (SMA),
and a silicone tourniquet catheter was positioned
around the vessel. An ultrasonic flow-probe (1RS;
Transonic Systems Inc, Ithaca, NY) was placed
around the SMA to measure SMA flow. In each
group, baseline macrohemodynamic parameters
(MAP, CO, and SMA flow) were recorded after a
30-minute recovery period. Hemodynamic mea-
surements were taken at baseline, 30 minutes after
the induction of partial aortic occlusion (PAO),
before the release of PAO, and at 90 and
120 minutes.
The animals were allocated randomly into 2
groups. Group 1 (n = 7) underwent 1 hour of PAO
induced by controlled tightening of the tourni-
quet. The goal was to keep the MAP in the femoral
artery continuously between 30 and 40 mm Hg.
The MAP, CO, and SMA flow were recorded at
baseline, 30 minutes after the induction of PAO,
before the release of PAO, and at 90 and 120 mi-
nutes. Differences in MAP between the femoral
(MAPF) and the carotid arteries (MAPC), ie, prox-
imal and distal to the site of PAO, were recorded.
Group 2 (n = 6) served as sham-operated controls.
Surgical preparations and experimental proto-
col, day 1. Animals were placed in a supine
position on heating pads, and the left femoral
artery was cannulated for the recording of the
MAP and HR. After a midline abdominal incision,
the proximal part of the abdominal aorta was
dissected free between the diaphragm and the
origin of the SMA, and a silicone tourniquet
catheter was positioned around the vessel. An
infusion of Ringer’s lactate (10 mL kg1 h1) was
administered intraperitoneally throughout the ex-
periments. The baseline variables were determined
during a 30-minute control period. Group 1
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was induced for 1 hour by controlled tightening
of the tourniquet in group 2 (n = 8) and group 3
(n = 9). The goal was to keep the MAP in the
femoral artery continuously between 30 and
40 mm Hg. In groups 1 and 2, the vehicle for Ac-
PepA (a 5-minute infusion of 1 mL saline intrave-
nously [IV]) was administered into the tail vein,
whereas in group 3, the administration of AcPePA
(Biologica Co. Ltd, Nagoya, Japan) (4 mg kg1 in
1 mL saline in a 5-minute infusion IV) into the
tail vein started 15 minutes before the end of
PAO. The animals were observed for 90 minutes;
the beginning of PAO was denoted as 0 minutes.
The MAP and HR were recorded 4 times (at base-
line, at 30 minutes after the induction of PAO,
before the release of PAO, and 30 minutes after
the end of PAO). In each group, intravital videomi-
croscopy was performed in the baseline condition
to examine the microcirculation of the serosa of
the ileum 5 cm proximal from the cecum (see
below). After the observation period, the femoral
catheter was removed carefully, the wounds were
closed, and the animals were allowed to recover.
In the event of any signs of hind limb ischemia,
the experiments were terminated, and the animals
were excluded from the study (n = 3).
Experimental protocol, day 2. At 24 hours after
the original operation, the animals were reanes-
thetized (sodium pentobarbital, 50 mg kg1 intra-
peritoneally), tracheostomy was performed to
facilitate spontaneous breathing, and the right ju-
gular vein was cannulated with PE50 tubing for
drug administration and infusion of Ringer’s
lactate (10 mL kg1 h1 IV). The left common ca-
rotid artery was cannulated with PE50 tubing for
measurements of MAP and HR. A thermistor-tip
catheter (PTH-01; Experimetria Ltd) was posi-
tioned into the ascending aorta through the right
common carotid artery for measurements of CO,
using a thermodilution technique with a com-
puter program (SPEL Advanced Cardiosys 1.4).
The abdominal wound was reopened, and an ul-
trasonic flow-probe was placed around the
exposed SMA (1RS; Transonic Systems Inc) to
measure the SMA flow. In each group, macrohe-
modynamic parameters were recorded after a
30-minute recovery period, and intravital videomi-
croscopy was performed to examine the microcir-
culation of the ileal mucosa 5 cm proximal from
the cecum. Through another incision, fluores-
cence confocal laser scanning endomicroscopy
(CLSEM) was performed for in vivo histologic in-
vestigations. At the end of the experiments, blood
samples were taken from the inferior caval veinfor determination of the plasma tumor necrosis
factor (TNF)-a, high-mobility group box protein-
1 (HMGB-1), and endothelin-1 (ET-1) levels.
Tissue samples were taken from the ileum for con-
ventional histologic examinations and detection
of leukocyte accumulation, and the animals were
then humanely killed with an overdose of
pentobarbital.
Hemodynamic measurements. Pressure signals
(BPR-02 transducer; Experimetria Ltd) and SMA
flow signals (T206 Animal Research Flowmeter;
Transonic Systems Inc) were measured continu-
ously and registered with a computerized data
acquisition system (Experimetria Ltd).
Intravital videomicroscopy of the ileal microcir-
culation. An intravital orthogonal polarization
spectral imaging technique (Cytoscan A/R, Cyto-
metrics, Philadelphia, PA) was used for visualiza-
tion of the serosal and mucosal microcirculation of
the ileum. This technique uses reflected polarized
light at the wavelength of the isosbestic point of
oxyhemoglobin and deoxyhemoglobin (548 nm).
Because polarization is preserved in reflection,
only photons scattered from a depth of 200 mm
contribute to image formation. A 103 objective
was placed onto the serosal surface of the ileum,
and microscopic images were recorded with an
S-VHS video recorder 1 (Panasonic AG-TL 700,
Matsushita Electric Ind. Co. Ltd, Osaka, Japan).
Quantitative assessment of the microcirculatory
parameters was performed off-line by frame-to-
frame blinded analysis of the videotaped
images. Changes in red blood cell velocity
(RBCV; mm s1) in the postcapillary venules were
determined in 3 separate fields by means of a
computer-assisted image analysis system (IVM Pic-
tron, Budapest, Hungary). All microcirculatory
evaluations were performed by the same investi-
gator (GV).
Plasma TNF-a, HMGB-1, and ET-1 measure-
ments. Blood samples (0.5 mL) were taken from
the inferior caval vein into precooled, heparizined
(100 U mL1) polypropylene tubes, centrifuged at
1,000 g at 48C for 30 minutes, and stored at 708C
until assay. Plasma TNF-a concentration was deter-
mined in duplicate by means of a commercially
available, enzyme-linked immunosorbent assay
(Quantikine ultrasensitive ELISA kit for rat TNF-
a; Biomedica Hungaria Kft, Budapest, Hungary).
The plasma level of HMGB-1 was measured with
a commercially available HMGB-1 ELISA kit
(Shino-Test, Kanagawa, Japan). Concentrations of
ET-1 in the plasma were investigated with a
commercially available kit (Biochemica Hungaria
Kft., Budapest, Hungary).
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leukocytes. Full-thickness ileum biopsies taken at
the end of the experiments were analyzed in each
group. The tissue was fixed in 6% buffered
formalin, embedded in paraffin, cut into 4-mm-
thick sections, and stained with hematoxylin
and eosin. The infiltration of leukocytes was
counted as the number of leukocytes in at least
20 fields of view at an original magnification of
4003. Blinded evaluation was performed by the
same investigator (SS).
In vivo detection of structural and microvas-
cular damage of the mucosa–fluorescence CLSEM.
The extent of microvascular damage of the termi-
nal ileum was evaluated by means of fluorescence
CLSEM (Five1; Optiscan Pty. Ltd, Melbourne,
Victoria, Australia) developed for in vivo histology.
Records were taken on day 2 for observation of the
effects of treatment with the C5a inhibitor. The
mucosal surface of the terminal ileum 5 cm
proximal to the cecum was exposed surgically
and laid flat for examination.
The microvascular structure was recorded after
the IV administration of 0.3 mL of fluorescein
isothiocyanate-dextran (FITC-dextran 150 kDa,
20 mg mL1 solution dissolved in saline, Sigma,
St Louis, MO). The objective of the device was
placed onto the mucosal surface of the ileum,
and confocal imaging was performed 5 minutes af-
ter dye administration (1 scan per image, 1024 3
1024 pixels and 475 3 475 mm per image).
The injury of the mucosal architecture was
examined after topical application of the fluores-
cent dye acriflavin (Sigma). The surplus dye was
washed off the mucosal surface of the ileum with
saline 2 minutes before imaging. Nonoverlapping
fields from the PAO group were compared with
samples from the AcPepA-treated and control
groups by using a semiquantitative scoring system
relating to the following aspects:
I. The structure of the microvessels (0 = normal,
1 = dye extravasation, but the vessel structure still
recognizable, 2 = destruction, and the vessel struc-
ture unrecognizable);
II. Denudation of villi (0 = no denudation, 1 = at
least 1 area denuded per field of view, 2 = more
than 1 area denuded without a recognizable villus
structure per field of view);
III. Edema (0 = no edema, 1 = moderate epithelial
swelling, 2 = severe edema);
IV. Shedding cells (0 = a normal, clear, well-defined
villus structure without shedding cells, 1 = some
shedding cells, but <30 cells per field of view,2 = more than 30 shedding cells per field of
view, 3 = severe debris);
V. Epithelial gap (0 = no gap, 1 = some gaps, but <5
per villus, 2 = more than 5 gaps per villus); and
VI. Longitudinal fissure on villi (0 = no fissure,
1 = fissure present).
Blinded analysis was performed twice separately
by 2 investigators (MN and GV).
Statistical analysis. Data analysis was performed
with a statistical software package (SigmaStat for
Windows, Jandel Scientific, Erkrath, Germany).
The Friedman repeated measures analysis of vari-
ance on ranks was applied within groups. Time-
dependent differences from the baseline for each
group were assessed by Dunn’s method. Differ-
ences between groups were analyzed with Kruskal–
Wallis 1-way analysis of variance on ranks, followed
by Dunn’s method for pairwise multiple compari-
son. Differences between groups in the pilot study
were analyzed by the Mann–Whitney U test, fol-
lowed by Dunn’s method for pairwise multiple
comparison (Table). In the figures, median values
and 75th and 25th percentiles are given.
RESULTS
Acute changes in hemodynamics in pilot studies.
In these experiments, the MAP, CO, and the SMA
flow were monitored to gain information about the
circulatory changes induced by PAO and to verify
the decrease in the SMA flow. During PAO, while
the MAPF was between 30 and 40 mm Hg, the
MAPC was initially increased significantly relative
to both the baseline values of the general MAP
and the sham-operated MAPC values, but it later
differed significantly only from the baseline values.
The CO started to decrease after 30 minutes of
PAO and reached a significant difference
compared with the sham-operated group and the
baseline values by the end of PAO. The general
MAP was increased significantly at 30 minutes after
the relief of PAO and then returned gradually to
the control level by the end of the observation
period. The CO started to increase after the
PAO, and no differences were detected during
the postocclusion period. The SMA flow decreased
significantly during the PAO and remained signifi-
cantly less than the baseline and sham-operated
values up to the end of the experiments (Table).
The AcPepA treatment did not have significant
effects on the hemodynamic parameters in sham-
operated animals (n = 6; data not shown).
Day 1, hemodynamic changes. In the sham-
operated animals, there were no changes in the
Table. Changes in mean arterial pressure [mm Hg], cardiac output (mL min1 kg1) and superior
mesenteric artery flow (mL min1) on day 1
Variable Parameters Baseline
30 min
(carotid artery)
60 min
(carotid artery)
90 min 120 min
30 min
(femoral artery)
60 min
(femoral artery)
Mean arterial pressure during partial aortic occlusion on day 1
Sham operated Median
25p; 75p
106.0
88.9; 111.2
107.0
88.9; 119.7
112.5
87.63; 122.1
103.5
86.1; 116.0
108.2
67.6; 122.5
105.5
90.5; 113.3
109.6
89.5; 122.0
PAO Median
25p; 75p
107.5
99.0; 113.8
147.0*x
139.8; 158.8
133.1*
121.8; 142.5
128.5*x
122.0; 135.2
109.3
103.4; 119.1
37.5*x
31.8; 41.3
37.5*x
30.7; 41.2
Variable Parameters Baseline 30 min 60 min 90 min 120 min
Cardiac output during partial aortic occlusion on day 1
Sham operated Median
25p; 75p
210
205; 217
216
197; 229
217
187; 237
204
195; 232
216
189; 225
PAO Median
25p; 75p
206
200; 214
206
181; 250
164*x
150; 178
184
173; 210
203
181; 225
Superior mesenteric artery flow during partial aortic occlusion on day 1
Sham operated Median
25p; 75p
14.2
12.3; 16.0
14.0
11.8; 17.0
14.9
14.1; 15.8
14.6
13.6; 19.7
15.2
12.5; 18.6
PAO Median
25p; 75p
15.3
13.8; 15.6
1.4*x
1.8; 2.1
2.1*x
1.2; 2.6
10.8*x
9.2; 12.1
8.6*x
8.3; 10.2
*P < .05 within groups vs baseline values (Friedman and Dunn test); x P < .05 partial aortic occlusion (PAO) group vs sham-operated group (Mann–Whit-
ney and Dunn test).
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was kept between 30 and 40 mm Hg for 1 hour.
The MAP was significantly greater in the PAO
group compared with the control group 30 mi-
nutes after the release of PAO. AcPepA did not
influence these parameters. As concerns the
values of the serosal microcirculation measured
in the control period before PAO, there was no
difference between the groups (Fig 1, A).
Day 2, hemodynamic changes. On day 2, MAP
did not differ between the groups or relative to the
baseline values measured on day 1. The operative
interventions caused an increase in HR by day 2.
Nonetheless, the HR was significantly greater in
the PAO group compared with the sham-operated
animals, and the HR did not increase after AcPepA
relative to that for the sham-operated group. The
SMA flow in the treated group remained at the
control level, whereas in the nontreated group it
was significantly greater in comparison with the
sham-operated group. The increased CO was
significantly decreased by C5a inhibitor on day 2
(Figs 1 and 2). On day 2, both the serosal and
mucosal RBCV were significantly decreased incomparison with the sham-operated group. Ac-
PepA resulted in a significantly greater RBCV
(Fig 3, A and B).
Changes in biochemical parameters. Concentra-
tions of the inflammatory mediators TNF-a and
HMGB-1 were significantly increased 24 hours
after the ischemic insult. The C5a inhibitor treat-
ment decreased the levels of both TNF-a and
HMGB-1 (Fig 4, A and B). The level of ET-1, an
important vasoconstrictor that can be responsible
for the impairment of the mucosal microcircula-
tion, was also increased on the day after PAO
(Fig 3, C). The administration of AcPepA
decreased the ET-1 concentration significantly.
Tissue leukocyte accumulation. On day 2 of the
experiments, a significant leukocyte accumula-
tion was observed in the PAO group compared
with the sham-operated animals. The administra-
tion of AcPepA significantly decreased the
leukocyte infiltration of the small intestinal wall
(Fig 4, C).
Microvascular and structural damage of the
mucosa. The microvessels in the villi were visual-
ized by FITC-dextran administration, and the
Fig 1. Changes in mean arterial pressure in the sham-operated (empty circles joined by a thin continuous line; empty box),
partial aortic occlusion (PAO; black squares joined by a continuous line; gray box), and PAO+acetyl-peptide-A (PAO+Ac-
PepA; empty triangles with continuous line; striped empty box) groups (A). Changes in heart rate in the sham-operated
(empty box), PAO (gray box) and PAO+AcPepA (striped empty box) groups (B). The plots demonstrate the median (horizon-
tal line in the box) and the 25th and 75th percentiles. *P < .05 for groups versus baseline values, xP < .05 for groups
versus sham-operated group values.
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acriflavin staining. In the PAO group, the CLSEM
evaluation demonstrated significant tissue
damage in contrast with the sham-operated group
(Fig 5). The vessel structure was disorganized,
and fluorescent dye leakage could be observed.
The acriflavin staining of the surface of the villi
revealed the presence of longitudinal fissures
and epithelial gaps and a large amount of debris
(Fig 6, A–C).
Administration of the C5a inhibitor AcPepA
decreased the mucosal damage and significantly
influenced the changes in both the microvas-
cular structure and the epithelial morphology ofthe small intestine. These changes were more
emphasized than in the sham-operated group,
but the degree of injury was decreased, as shown
by the decreased level of dye leakage relative to
the nontreated PAO group (Fig 6, D–F).DISCUSSION
NOMI is an often nonappreciated complication
of low-flow conditions5 and a better understanding
of the process is demanded if the current thera-
peutic possibilities are to be improved. The
methods used at present to treat NOMI, such as
the direct application of vasodilator agents into
Fig 2. Changes in cardiac output index (A) and in SMA flow (B) in the sham-operated (empty box), partial aortic occlu-
sion (PAO; gray box), and PAO+acetyl-peptide-A (PAO+AcPepA; striped empty box) groups. The plots demonstrate the me-
dian (horizontal line in the box) and the 25th and 75th percentiles. xP < .05 for groups versus sham-operated group
values. #P < .05 between AcPepA-treated group versus PAO group.
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which may limit the relevance of otherwise effec-
tive vasoactive treatment.This study involved the first application of a rat
model, with which the main clinical features of
NOMI could be reproduced. The key elements of
Fig 3. Changes in serosal (A), mucosal (B), RBCV and plasma ET-1 level (C) in the sham-operated (empty box), partial
aortic occlusion (PAO; gray box), and PAO+acetyl-peptide-A (PAO+AcPepA; striped empty box) groups. The plots demon-
strate the median (horizontal line in the box) and the 25th and 75th percentiles. xP < .05 for groups versus sham-
operated group values. #P < .05 between AcPepA-treated group versus PAO group.
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after an extramesenteric insult and a low level of
invasiveness, which makes long-term observations
possible. In this context, we obtained conclusive
evidence of a significantly decreased SMA blood
flow after partial occlusion of the subdiaphrag-
matic aorta, which persisted during the 24-hour
postocclusion period, despite the compensated
CO and MAP (Table). It should be added that
the late hemodynamic changes were characteristic
of a systemic inflammatory response syndrome.
Although the MAP was in the normal range, the
HR and CO were significantly increased as a part
of the compensatory mechanism. During the early
phase of systemic inflammation, the oxygen de-
mand was in all likelihood enhanced owing to
the high metabolic rate. To meet this need, oxygen
delivery was increased, mostly through an increase
in CO. Nonetheless, we suggest that the oxygena-
tion of the cells cannot be improved without a
properly functioning microcirculation, and a dete-
rioration of the capillary perfusion will prevent theoxygen consumption despite the seemingly
increased delivery. In our model, the small intesti-
nal microcirculation was significantly impaired
24 hours after the insult, as shown by the
decreased RBCV at both the serosal and mucosal
surfaces. This observation suggests that microcircu-
latory damage was present in the gastrointestinal
wall despite the normal or increased SMA flow.14
Activation of the complement system is a key
element for the induction of ischemia–reperfusion
injury. During the process, complement activation
can take place by all 3 known routes (classic, lectin,
and alternative). Activation of the complement
cascade system is a complex process that results in
the formation of the membrane attack complex,
an important component of the innate immune
system.6
During the process, however, biologically active
toxic molecules are produced such as the anaphy-
latoxins C3a and C5a. One of the most important
direct effects of C5a, a potent chemoattractant, is
the accumulation of neutrophilic leukocytes.
Fig 4. Changes in plasma tumor necrosis factor-a (A), high-mobility group box protein-1 (B) levels, and small intestinal
leukocyte infiltration (C) in the sham operated (empty box), partial aortic occlusion (PAO; gray box) and PAO+acetyl-
peptide-A (PAO+AcPepA; striped empty box) groups. The plots demonstrate the median (horizontal line in the box)
and the 25th and 75th percentiles. xP < .05 for groups versus sham-operated group values; #P < .05 between
AcPepA-treated group versus PAO group.
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increased level of tissue injury by releasing reactive
oxygen species and proinflammatory agents.6 This
process is also obvious in our experimental setup;
in addition to the presence of increased neutro-
phil infiltration as a consequence of the PAO,
the occurrence of tissue damage is verified by the
CLSEM records. The C5a inhibitor that we used
decreased these changes, similarly to known C5a
receptor antagonists and C5a antibodies.
The considerable number of studies on C5a
receptor agonists and C5a antibodies illustrate the
great demand for effective C5a antagonists.6,15,16
Despite the promising experimental results, very
few of these agents have found their way into clin-
ical applications, and they have very limited effi-
cacy. The discrepancy between the experimental
and clinical results may be owing to the large
amount of C5a receptors resulting from upregula-
tion during inflammatory processes. Despite treat-
ment with C5a receptor agonists, there are still
sufficient C5aRs to maintain function.12 As con-
cerns the C5a antibodies, the possible cross-reactions with other complement components
may reduce the efficacy of the treatment by scav-
enging the C5a antibodies or causing undesirable
side effects.
The C5a inhibitor AcPepA, however, was de-
signed to cover the receptor-binding region of the
human C5a, and its high-affinity binding was
proved in vitro. Moreover, AcPepA is effective
against C5a generation in several species,
including rodents, swine, and primates,12,17-19
and decreases the hypersensitivity reaction in hu-
man lung tissues in vitro.20 The wide variety of spe-
cies in which AcPepA has proved effective suggests
its promise as regards the issue of the translation of
experimental and clinical results.
In the AcPepA-treated group, the small intestinal
RBCV was significantly greater on day 2, and the
improved microcirculation was present without in-
creases in CO and SMA flow, which may reflect a
better efficacy of oxygen extraction. The decreased
ET-1 level after AcPepA treatment may have contrib-
uted to the improvement of the small intestinal
microcirculation, and the altered proinflammatory
Fig 5. Level of mucosal injury according to the confocal
laser scanning endomicroscopy (CLSEM) in vivo histo-
logic records in the sham-operated (empty box), partial
aortic occlusion (PAO; gray box), and PAO+acetyl-
peptide-A (PAO+AcPepA; striped empty box) groups. The
plots demonstrate the median (horizontal line in the
box) and the 25th and 75th percentiles. xP < .05 for
groups versus sham-operated group values; #P < .05 be-
tween AcPepA-treated group and PAO group.
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in inflammatory activation as a consequence of C5a
inhibitor therapy. ET-1 is among the most impor-
tant vasoconstrictive factors in the splanchnic
microcirculation, and administration of a selective
endothelin type A receptor antagonist improves the
small intestinal microcirculation significantly under
low-flow conditions.21 More important, the exces-
sive release of ET-1 enhances leukocyte activation
in the postcapillary venules of the small intestine,22
which may exacerbate the local tissue damage
further.
The plasma levels of HMGB-1 and TNF-a are
another important feature of our model, and these
findings are in accord with the clinical observa-
tions.23 A high level of TNF-a can impair directly
gastrointestinal epithelial tight junctions,24 and a
decreased level of TNF-a in the AcPepA-treated
group may, therefore, not only be a direct sign of
the alleviated inflammatory cascade activation,
but may also be associated indirectly with the pres-
ervation of the barrier function. Similarly,
increased output of HMGB-1 can amplify the in-
flammatory signals, and a significant decrease in
the plasma level of HMGB-1 may be a key sign of
the decreased systemic inflammatory response.21
HMGB-1 is a highly potent alarmin originating
from necrotic cells or actively released from im-
mune cells, which causes leukocyte recruitment
and the release of other inflammatory cytokines.25
The release is mediated directly by C5a throughC5L2 receptors, and the blockade or absence of
C5L2 receptors improves the survival in murine
sepsis.26 The net result of a decrease in the release
of HMGB-1 and TNF-a is decreased leukocyte
accumulation. This was verified by traditional his-
tology; the level of leukocyte infiltration was signif-
icantly less in the small intestinal wall in the
AcPepA-treated group. All these macrocirculatory
and microcirculatory and inflammatory effects of
PAO culminated in visible damage of the mucosa
(Fig 5), whereas C5a inhibition resulted in a signif-
icant decrease in tissue damage with a preserved
villus structure and microvascular architecture,
demonstrated by in vivo histology.
In general, it must be acknowledged that rat
models have a number of limitations from the
aspect of the extrapolation of experimental animal
data to the human patient, such as differences in
age, comorbidities, the timing of treatments,
dosages and dose-dependent efficacies, and the
lack of more complex intensive care in the
animals.27 It is also important to note certain addi-
tional limitations of the present experimental
model. One of these is the significantly increased
MAPC that develops proximal to the site of the
PAO. This increase in MAPC approximates the up-
per limits of the cerebral autoregulation28 for a
short period, during the first 30 minutes of the
PAO. Nevertheless, this rat model is tolerable,
because no animals died during the first 24 hours,
and none showed any signs of central nervous sys-
tem injury. Another problematic point is the need
for invasive measurement of blood pressure in the
femoral artery because this provides more precise
data for the adjustment of PAO compared with
noninvasive measurements. During the design of
the model, we took into consideration the well-
developed collateral vascularization in the rat
hind limb, which can provide adequate tissue
perfusion even after ligation of the femoral ar-
tery.29,30 Nevertheless, before the recovery period,
the animals were kept under observation and, in
the event of any signs of permanent hind limb
ischemia, such as cyanosis or stiffness, the experi-
ment was terminated, and the animal was excluded
from the study. The low number of such animals
(n = 3) suggests that ligation of the femoral artery
is possible in these studies.
In conclusion, we characterized some of the
potentially detrimental circulatory and pro-
inflammatory consequences of nonocclusive
mesenteric hypoperfusion. In this experimental
setup, a single IV dose of the C5a antagonist
AcPepA improved the local circulatory changes
and decreased the secondary mucosal damage in a
Fig 6. In vivo histologic (confocal laser scanning endomicroscopy; CLSEM) records showing the changes in the epithe-
lial surface 24 hours after the partial aortic occlusion (PAO; acriflavin staining) in the sham-operated (A), PAO (B), and
PAO+acetyl-peptide-A (PAO+AcPepA; C) groups. Changes in the microvascular structure were visualized with CLSEM
after intravenous administration of fluorescein isothiocynate (FITC)-dextran in the sham operated (D), PAO (E),
and PAO+AcPepA (F) groups (475 3 475 mm per image).
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970 Erces et alrelatively wide time frame, at least 24 hours after
the insult. The relevance of these data in the
clinical situation in man remains unknown, but
this approach is of promise for use in NOMI-
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